ProCE Banner Activity

ECOG-ACRIN E1910: Phase III Study of Consolidation Chemotherapy ± Blinatumomab in MRD-Negative BCR::ABL1-Negative B-ALL

Slideset Download
Conference Coverage

Consolidation therapy with blinatumomab plus chemotherapy confers a significant OS benefit compared with consolidation chemotherapy alone in adult patients with MRD-negative BCR::ABL1-negative B-lineage acute lymphoblastic leukemia.

Released: December 15, 2022

Expiration: December 14, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen